Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Acetate[1] Acetate---[43] 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 227, 235, 265, 288, 298, 299
2ALX-0081----[1] 64
3Anfibatide[1] Anfibatide---[1] 64
4Anti-von Willebrand Factor Nanobody[1] Von Willebrand factor human---[1] 64
5Anti-von Willebrand Factor Nanobody, Caplacizumab[2] Caplacizumab,
Von Willebrand factor human		[1] D11160 [1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64
6Anti-von Willebrand Factor Nanobody, INN = Caplacizumab[2] Caplacizumab,
Von Willebrand factor human		[1] D11160 [1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64
7Apadamtase alfa[1] Apadamtase alfa---[1] 64
8Apademtase alfa----[1] 64
9ARC 1779----[2] 64, 288
10ARC1779----[2] 64, 288
11ARC1779 Injection----[2] 64, 288
12BAX930----[1] 64
13BAX930 - RECOMBINANT HUMAN ADAMTS13----[1] 64
14BAX930 or SHP655----[1] 64
15BORTEZOMIB[1] Bortezomib[1] D03150 [1] PSMB5 💬[8] Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬[16] 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331
16Bortezomib Injection[1] Bortezomib[1] D03150 [1] PSMB5 💬[8] Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬[1] 64
17CABLIVI[1] Caplacizumab[1] D11160 [1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64
18Cablivi®[1] Caplacizumab[1] D11160 [1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64
19CAPLACIZUMAB[1] Caplacizumab[1] D11160 [1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64
20Caplacizumab (ALX-0081)[1] Caplacizumab[1] D11160 [1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64
21Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)[2] Caplacizumab,
Von Willebrand factor human		[1] D11160 [1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64
22Caplacizumab (an anti-von Willebrand Factor Nanobody)[2] Caplacizumab,
Von Willebrand factor human		[1] D11160 [1] VWF 💬[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64
23Corticosteroid treatment (Methylprednisolone or prednisolone)[2] Methylprednisolone,
Prednisolone		[14] D00407 ,
D00472 ,
D00751 ,
D00979 ,
D00980 ,
D00981 ,
D00982 ,
D01239 ,
D01998 ,
D02156 ,
D03301 ,
D05000 ,
D05001 ,
D05002 		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 64
24Corticosteroids----[10] 41, 46, 49, 64, 97, 107, 164, 220, 296, 300
25Cryosupernatant plasma----[1] 64
26Cyclosporine[1] Cyclosporine[1] D00184 [5] PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		[33] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬[37] 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302
27Danazol[1] Danazol[1] D00289 [3] AR,
ESR1,
PGR 💬		[12] Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬[5] 60, 63, 64, 65, 285
28Desmopressin[1] Desmopressin[2] D00291 ,
D02235 		[2] AVPR2,
F8 💬		[4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[5] 6, 64, 72, 225, 288
29Desmopressin acetate[2] Acetate,
Desmopressin		[2] D00291 ,
D02235 		[2] AVPR2,
F8 💬		[4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[2] 64, 288
30Dexamethasone[1] Dexamethasone[9] D00292 ,
D00975 ,
D01510 ,
D01615 ,
D01632 ,
D01948 ,
D02174 ,
D02591 ,
D02592 		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
31HMED-IdeS[1] Imlifidase[1] D11470 --[2] 64, 221
32IDEC-C2B8, Ro 45-2294----[1] 64
33IdeS[1] Imlifidase[1] D11470 --[2] 64, 221
34IdeS (0.25 mg/kg)[1] Imlifidase[1] D11470 --[1] 64
35IdeS (0.50 mg/kg)[1] Imlifidase[1] D11470 --[1] 64
36Immunosuppressive treatment (eg, rituximab)[1] Rituximab[1] D02994 [1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 64
37MabThera[1] Rituximab[1] D02994 [1] MS4A1 💬[1] Hematopoietic cell lineage 💬[22] 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271
38Magnesium[1] Magnesium---[19] 3, 6, 11, 13, 15, 46, 64, 70, 93, 97, 166, 225, 235, 256, 284, 291, 296, 297, 298
39MASP-2 antibody[1] Narsoplimab[1] D11531 [1] MASP2 💬[3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[3] 64, 66, 109
40Methylprednisolone[1] Methylprednisolone[6] D00407 ,
D00751 ,
D00979 ,
D05000 ,
D05001 ,
D05002 		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
41Minirin[1] Desmopressin[2] D00291 ,
D02235 		[2] AVPR2,
F8 💬		[4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[2] 64, 288
42Octaplas[1] Plasma protein fraction (human)---[1] 64
43Octaplas infusion[1] Plasma protein fraction (human)---[1] 64
44Octaplas SD[1] Plasma protein fraction (human)---[1] 64
45OctaplasLG®----[1] 64
46Octaplas®LG[1] Plasma protein fraction (human)---[1] 64
47Octostim----[2] 64, 288
48OMS721----[3] 64, 66, 109
49OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody[1] Narsoplimab[1] D11531 [1] MASP2 💬[3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[2] 64, 109
50OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody[1] Narsoplimab[1] D11531 [1] MASP2 💬[3] Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬[2] 64, 109
51Other: standard of care----[7] 13, 49, 64, 85, 96, 245, 246
52Plasma exchange----[5] 13, 43, 44, 64, 222
53Plasma exchange (PE)----[3] 64, 66, 220
54Pooled Plasma (Human), Solvent/Detergent Treated----[1] 64
55PREDNISOLONE[1] Prednisolone[8] D00472 ,
D00980 ,
D00981 ,
D00982 ,
D01239 ,
D01998 ,
D02156 ,
D03301 		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[43] 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
56Prednisone[1] Prednisone[1] D00473 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[48] 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
57RADAMTS-13----[1] 64
58Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13----[1] 64
59Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1----[1] 64
60Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs----[1] 64
61Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13----[1] 64
62Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 (rADAMTS13)----[1] 64
63Recombinant ADAMTS13----[1] 64
64Rituximab[1] Rituximab[1] D02994 [1] MS4A1 💬[1] Hematopoietic cell lineage 💬[49] 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
65Romiplostim[1] Romiplostim[1] D08990 [1] MPL 💬[2] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬[4] 60, 63, 64, 65
66SHP 655 (BAX 930)----[1] 64
67SHP655----[1] 64
68Standard of Care----[10] 6, 13, 46, 49, 51, 63, 64, 79, 171, 271
69Standard Plasma----[1] 64
70Standrd of Care treatment----[1] 64
71Sulfate[1] Sulfate ion---[27] 2, 3, 6, 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 79, 85, 86, 96, 111, 218, 222, 226, 265, 296, 297, 299
72Sulfate, Magnesium[2] Magnesium,
Sulfate ion		---[1] 64
73TAK-755----[1] 64
74TAK-755 or BAX930 or SHP655----[1] 64
75TAK-755 orBAX930 or SHP655----[1] 64
76Uniplas----[1] 64
77Von willebrand factor[1] Von Willebrand factor human---[2] 64, 288